Premium
EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Author(s) -
Tam C.S.,
Byrd J.C.,
O'Brien S.,
Coutre S.,
Barr P.M.,
Furman R.R.,
Kipps T.J.,
Burger J.A.,
Stevens D.,
Sharman J.,
Ghia P.,
Flinn I.,
Zhou C.,
Ninomoto J.,
James D.F.,
Wierda W.G.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_96
Subject(s) - medicine , ibrutinib , ven , tumor lysis syndrome , venetoclax , bendamustine , neutropenia , chronic lymphocytic leukemia , gastroenterology , lymphocytosis , oncology , surgery , leukemia , toxicity , chemotherapy , computer security , computer science